By now, the argument for Africa’s inclusion in global clinical research is well established. The scientific rationale is clear. The public health need is clear. The access imperative is clear.
But sponsors do not place complex Phase II and III trials solely on the strength of unmet need, scientific rationale, or access imperatives.
They place them where they believe delivery risk can be managed.
That is the more important conversation for African research networks today. The opportunity is not simply to prove that Africa should be included. It is to show that inclusion can be executed predictably, across countries, sites, regulators, investigators, and data systems.
A network with many sites may look impressive on a map. But if every site contracts differently, interprets procedures differently, reports progress differently, and escalates issues through different channels, the sponsor still experiences fragmentation.
From the sponsor’s perspective, that is not yet an operational network. It is a collection of relationships.
The strategic value of a network lies not in how many dots appear on a map, but in whether those dots can move together.
What Sponsors Can and Cannot Delegate
Sponsors may delegate trial-related activities, but they cannot fully transfer regulatory responsibility for trial quality, participant safety or data integrity (1).
Regulatory guidance under ICH E6(R3) and FDA oversight frameworks (2) has consistently reinforced that the division of responsibility between sponsors, investigators, sites, and partners is not a technical detail (1). It shapes the ethical, legal, and operational accountability of the entire trial.
What sponsors can delegate are operational activities and defined responsibilities.
And the activities they most want to delegate to a credible network are the ones that consume internal time, budget, and leadership attention: country and site identification, feasibility, contracting, regulatory submissions, investigator training, monitoring oversight, enrollment troubleshooting, vendor coordination, and risk-based quality management across multiple geographies.
This is why serious networks matter.
They reduce coordination cost. They turn fragmented local capability into sponsor-readable delivery capacity. A strong network does not replace sponsor accountability. It makes accountability executable.
The Four Things Sponsors Are Really Evaluating
When sponsors evaluate a network, they are not simply asking whether it has good investigators. They are asking whether the network can behave like a system.
First, governance. Who makes decisions? Who can resolve disputes, reallocate resources, escalate risk, and stand behind commitments?
Second, standardization. Does what works at one site work the same way at the next? Are SOPs, training expectations, data practices, start-up processes, and quality controls consistent enough to create confidence?
Third, visibility. Can the sponsor obtain timely operational visibility across countries and sites? Not through polished quarterly updates, but through operational signals: start-up milestones, enrollment progress, deviations, query aging, monitoring findings, and corrective actions.
Fourth, delivery assurance. Has the network done it before? Can it show verifiable performance data? Sponsors do not invest in aspiration alone. They invest in evidence of repeatable execution.
These are the features that turn a network from a collection of sites into a sponsor-readable delivery system.
Across the clinical research sector, regulators and sponsors increasingly recognize that trial complexity is placing pressure on traditional governance and oversight models. Decentralized methods, digital tools, multi-country execution, and increasingly complex data flows all create new points of failure when decision rights, oversight, and escalation pathways are unclear.
The lesson is highly relevant for Africa. Innovation without aligned quality systems and governance structures can create operational fragmentation. Strong site relationships matter, but engagement alone is not enough. Trust keeps sites invested; operational precision keeps trials compliant, on schedule, and inspection-ready.
Increasingly, sponsors also evaluate whether networks can support centralized oversight through interoperable data systems, risk-based quality management approaches, and inspection-ready documentation practices.
What a Serious Continental Network Should Offer
A sponsor-ready African network should offer five things:
- A single contracting pathway across multiple countries, supported by pre-negotiated positions where possible.
- A common operating system across sites, including shared SOPs, training standards, quality metrics, and escalation routines.
- A governance structure with clear decision rights, so sponsors know who is accountable for what.
- Verifiable performance data, not only on enrollment but on cycle times, data quality, query resolution, inspection readiness, and retention.
- A regulatory liaison function that engages national authorities and regional harmonization efforts as partners in execution, not as late-stage bottlenecks
The move toward a more coordinated continental regulatory architecture through initiatives such as the African Medicines Agency (AMA) and the African Medicines Regulatory Harmonization (AMRH) program creates an opportunity to reduce duplication, strengthen regulatory capacity, and simplify multi-country research coordination (3). For sponsors, that matters because regulatory complexity is not just an administrative issue. It directly affects timelines, predictability, and confidence in execution.
The promise is significant, but realizing it will require careful coordination across national regulators, regional institutions, sponsors and research networks (4)
The Future Belongs to Coordinated Execution
Africa’s under-representation in clinical research is not explained by a lack of biology, patients, clinicians, or ambition alone.
The interface between African research capability and global sponsor requirements has often been fragmented, variable, and overly dependent on individual institutional relationships.
That interface is now ours to redesign.
The next era of African clinical research will not be won by the largest network on paper. It will be won by the network that gives sponsors confidence: confidence that timelines are real, standards travel, risks are visible, decisions are owned, and data can be trusted.
That is the value sponsors are buying: coordinated execution, not just scale.
References
- 21 CFR Part 312 Subpart D — Responsibilities of Sponsors and Investigators [Internet]. [cited 2026 May 8]. Available from: https://www.ecfr.gov/current/title-21/part-312/subpart-D
- Research C for DE and. E6(R3) Good Clinical Practice (GCP) [Internet]. FDA; 2025 [cited 2026 May 14]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp
- African Yearbook Of International L E. Treaty for the Establishment of the African Medicines Agency. Afr Yearb Int Law Online Annu Afr Droit Int Online. 2019 Dec 19;24(1):396–415. doi:10.1163/22116176_02401019
- Wairagkar N, Djoudalbaye B, Moubarak I, Zakari M, Shaffer DN, Ismail AJ, et al. The African Medicines Agency – A potential gamechanger that requires strategic focus. PLOS Glob Public Health. 2025 Feb 14;5(2):e0004276. doi:10.1371/journal.pgph.0004276